HOPE - HOPE

El interés en corto de Hope Bancorp da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Hope Bancorp. Los datos de interés en corto se actualizan cada dos semanas.

Hope Bancorp (NASDAQ:HOPE) Bolsa, Informe de interés en corto

Hope Bancorp

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.

Hope Bancorp Inc

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Overweight rating and announces Price Target of $20.

News

Price Target

Initiation

Analyst Ratings

BCRX

Cantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20

Morgan Stanley analyst James Faucette maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Equal-Weight and lowers the price target from $95 to $89.

QTWO

Morgan Stanley Maintains Equal-Weight on Q2 Holdings, Lowers Price Target to $89

DA Davidson analyst Gary Tenner maintains Sierra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSRR#NASDAQ">BSRR</a>) with a Buy and lowers the price target from $37 to $36.

BSRR

DA Davidson Maintains Buy on Sierra, Lowers Price Target to $36

Guidance

NEOV

NeoVolta Says Apr. Revenue Projected To Exceed $2M

HAFC

Hanmi President And CEO Bonnie Lee Releases Shareholder Letter Titled "Successfully Navigating a Dynamic Market Environment"

DA Davidson analyst Thomas Diffely maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and lowers the price target from $36 to $30.

AMKR

DA Davidson Maintains Buy on Amkor Tech, Lowers Price Target to $30

American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45062389/american-tower-corporation-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: American Tower reported first-quarter revenue of $2.56 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.54 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company also reported adjusted funds from operations (AFFO) of $2.75 per share, beating estimates of $2.58 per share.
Total revenue was up 2% year-over-year, while property revenue increased 0.2%. At quarter&#8217;s end, the company had approximately $11.7 billion of total liquidity, consisting of approximately $2.1 billion in cash and cash equivalents.
&#8220;Together with the resilient demand we&#8217;re seeing for our portfolio of assets, we remain focused on enhancing the quality of our earnings through active portfolio management, organizational and operational efficiency, disciplined capital allocation and a strong balance sheet, positioning us to better navigate ongoing macroeconomic uncertainty while continuing to meet our customers&#8217; critical connectivity needs,&#8221; said Steven Vondran,&nbsp;CEO of American Tower. 
See Also: <a href="https://www.benzinga.com/25/04/45064454/this-trade-desk-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Trade Desk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Outlook: American Tower expects total property revenue in 2025 to be between $9.97 billion and $10.12 billion. The company also raised its full-year AFFO guidance from a range of $10.31 to $10.50 to a new range of $10.35 to $10.54 per share, versus estimates of $10.39 per share.
AMT Price Action: <a href="http://benzinga.com/quote/amt">American Tower shares</a> were up 0.57% at $212.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: katjen/Shutterstock.

Movers

American Tower Reports Q1 Earnings: The Details

Morgan Stanley analyst Erik Woodring maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and raises the price target from $220 to $235.

AAPL

Morgan Stanley Maintains Overweight on Apple, Raises Price Target to $235

<ul>
<li>Following last week's <a href="https://www.whitehouse.gov/presidential-actions/2025/04/unleashing-americas-offshore-critical-minerals-and-resources/">Executive Order</a>, ‘Unleashing America's Offshore Critical Minerals and Resources', TMC USA has submitted applications to the National Oceanic and Atmospheric Administration (NOAA) for two exploration licenses and one commercial recovery permit under the Deep Seabed Hard Mineral Resources Act (DSHMRA)</li>
<li>The commercial recovery permit application advances TMC's timeline ahead of its original June 27 application target, further strengthening the Company's leadership in the deep-sea minerals sector</li>
<li>The application area for the commercial recovery permit, TMC USA-A_2, covers a total combined area of 25,160 square kilometers in the Clarion Clipperton Zone which includes areas that contain the Company's already indicated and measured resources</li>
<li>TMC USA has also submitted two exploration license applications: TMC USA-A and TMC USA-B with a total combined area of 199,895 square kilometers</li>
<li>We believe the TMC USA-A and USA-B exploration areas contain SEC SK 1300-compliant resources of 1,635 million wet tonnes of polymetallic nodules, with an additional estimated 500 million tonnes of exploration upside. Together, the resource is estimated to contain approximately 15.5 million tonnes of nickel, 12.8 million tonnes of copper, 2.0 million tonnes of cobalt, and 345 million tonnes of manganese &nbsp;</li>
</ul>
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) (TMC or the Company), an explorer of the world's largest undeveloped resource of critical metals for infrastructure, defense, energy and future technologies, today announced that its U.S. subsidiary, The Metals Company USA LLC (TMC USA), has submitted applications for a commercial recovery permit and two exploration licenses under the Deep Seabed Hard Mineral Resources Act (DSHMRA) and National Oceanic and Atmospheric Administration (NOAA) implementing regulations which form the U.S. seabed mining code.

TMC USA Submits Application For Commercial Recovery Of Deep-Sea Minerals In High Seas Under U.S. Seabed Mining Code

Morgan Stanley analyst Craig Hettenbach maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Equal-Weight and lowers the price target from $60 to $40.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $40

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) –
– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV) –
– Presentations in hepatitis B virus (HBV) and hepatitis C virus (HCV) will underscore Gilead's commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –

Biotech

Events

General

GILD

Gilead To Present New Research To EASL Congress

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.88 per share. This is a 14.29 percent increase over earnings of $0.77 per share from the same period last year. The company reported $20.17 million in sales this quarter. This is a 13.68 percent increase over sales of $17.74 million the same period last year.

Earnings

FRAF

Franklin Financial Servs Q1 EPS $0.88 Up From $0.77 YoY, Sales $20.17M Up From $17.74M YoY

ASBP

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval For In-Human Clinical Trial Protocol Of Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform rating and announces Price Target of $5.

PRQR

Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5

Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics

Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight and Sustained Outcomes for Care Providers

HCAT

MSFT

Health Catalyst Partners With Microsoft To Accelerate AI Adoption And Transformation For Care Delivery Organizations

WIIM

PMAX

Powell Max shares are trading lower after the company reported FY24 financial results.

EDAP

EDAP TMS shares are trading higher after the company announced the FARP study achieved its primary endpoint.

Johns Hopkins Medicine's Valerie Lee, MD joins Michael J. Pishvaian, MD in an Appointed Key Role for TIGeR-PaC Trial
By becoming an additional clinical site for TIGeR-PaC, Johns Hopkins Medicine joins several esteemed cancer centers to support RenovoRx's initiative to complete patient enrollment for the trial during 2025
&nbsp;

RNXT

Johns Hopkins Medicine Initiates Enrollment For RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) recalled over 877,000 vehicles with the 6.2-liter V8 engine due to possible defects. The company has also issued a stop-sale order for the affected models.
What Happened: The U.S. National Highway Traffic Safety Administration (NHTSA) had launched a probe into the engine after the agency received multiple complaints of engine failure. While the investigation is still ongoing, GM has issued the recall, <a href="https://www.caranddriver.com/news/a64611938/chevy-silverado-tahoe-cadillac-escalade-defective-v8-recall/">reported</a> Car and Driver on Tuesday.
GM says the issue stems from defects in the engine's crankshaft and connecting rods. All engines will be inspected by the company and will be repaired or replaced should there be any defects.
The company says the affected models — all manufactured from 2021-2024 — include the Cadillac Escalade and Escalade ESV. Chevrolet models like the Silverado 1500, Chevrolet Suburban, and Chevrolet Tahoe are also recalled. The list also includes the GMC Sierra 1500, Yukon, as well as Yukon XL.
GM did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The news comes in during an uncertain time for GM, and the U.S. auto sector at large, amid the rising U.S.-China trade tensions. Experts have suggested that companies like GM could <a href="https://www.benzinga.com/25/04/44756759/new-research-shows-donald-trumps-25-tariffs-could-cost-auto-companies-108billion-report">stand to lose billions</a> of dollars due to the auto tariffs.
GM, along with Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), also faces the risk of getting a negative rating, according to a report published by ratings agency S&amp;P, due to the auto tariffs. However, Donald Trump's decision to <a href="https://www.benzinga.com/25/04/45059191/donald-trump-will-reduce-impact-on-us-auto-industry-by-alleviating-some-auto-tarrifs-report">alleviate some tariffs</a> could prove to be a boost for GM.&nbsp;&nbsp;
Elsewhere, GM also faces a <a href="https://www.benzinga.com/25/04/44917481/general-motors-faces-fresh-lawsuit-for-alleged-violation-of-customers-privacy-report">multi-district lawsuit </a>for allegedly violating its customers' privacy by collecting and selling data without consent, which the company denies.
Price Action: GM Stock currently trades for $47.24 on the NYSE, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44916042/general-motors-has-no-plans-to-move-ev-production-away-from-mexico-despite-tariff-uncertainty">General Motors Has No Plans To Move EV Production Away From Mexico Despite Tariff Uncertainty</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Comments

Hope Bancorp

Interés en corto

Hope Bancorp (NASDAQ:HOPE) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL